A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Condition: Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Roche-Genetech

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03). This study is designed to evaluate whether consolidation therapy with the combination of the anti-TIGIT antibody tiragolumab with atezolizumab yields improved clinical benefit compared with durvalumab monotherapy in patients with locally advanced, unresectable Stage III NSCLC who have received at least two prior cycles of platinum-based CRT and have not progressed.


Go To Trial Homepage